Shionogi Of Japan Plans U.S. Focus On Metabolic Syndrome
This article was originally published in PharmAsia News
Japan's Shionogi acquired U.S.-based Sciele Pharma last year to give the Japanese firm a way to market its metabolic syndrome products, Shionogi President Isao Teshirogi says. He said his company wants to move away from its focus on antibiotics and give more emphasis to its medicines such as Crestor (rosuvastatin), marketed by AstraZeneca outside of Japan. Although Shionogi expects to continue to rely on Crestor as a major revenue source, the company faces a need for other sources of profit when the drug loses patent protection beginning in 2016. Teshirogi said the Sciele acquisition gives Shionogi a chance to use the U.S. firm's 800 medical representatives to sell an obesity drug it is developing. (Click here for more - a subscription may be required
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.